- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02216162
PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program (PROACTIVE)
PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program Including a Regular Physical Training, a Medical and Nutritional Follow-up, on Adjuvant Hormonal Treatment Compliance in Breast Cancer Patients Over 70 Years.
PROACTIVE randomized study to evaluate the impact of a multidimensional geriatric intervention on treatment compliance, measured regularly by blood dosing of drug metabolites.
Patients in the intervention group will be proposed:
- A regular geriatric follow up including an attentive screening of joint symptoms and functionality,
- An adapted treatment of join pain,
- Weekly sessions of adapted physical activity (Taï Chi),
- And a systematic correction of vitamin D deficits.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Lyon, Frankrike
- Claire Falandry
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 70 years old
- Non metastatic breast cancer, with or without node metastases
- Hormone Receptor (HR) positive breast cancer patients
- Women with breast adenocarcinoma, confirmed by a pathologist and who underwent surgery or radiotherapy
- Introduce an hormonal therapy during 5 years
- Life expectancy > 6 months (at the discretion of the investigator)
- Covered by a Health System where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research
- Patient must be available for follow-up
- Having given written informed consent prior to any procedure related to the study
Exclusion Criteria:
- No other primary malignant tumor < 5-years old except cured in situ cancer of the cervix, in situ urothelial cancer, or basocellular cancer
- Patient with an experimental treatment in the 30 days prior to the enrollment
- Evidence of metastatic disease
- Not under any administrative or legal supervision
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: A: Interventional adapted physical activity + enhanced geriatr
Geriatric (functionality, gait, nutrition) follow-up, biological tests, anti-aromatase agents blood dosing, clinical assessment.
Weekly Taï-Chi exercises.
|
Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk. A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36). |
Övrig: Arm B: control
Clinical follow-up according to the Guidelines, annual geriatric and nutritional assessment
|
Usual clinical follow-up
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Compliance of an adjuvant hormonal therapy
Tidsram: 3 years of follow up
|
Compliance rate is defined as the rate of blood samplings of anti-hormone metabolites in the therapeutic range, within the 7 blood samplings distributed in the 3 years of follow-up
|
3 years of follow up
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Intensity and duration of musculoskeletal adverse events
Tidsram: 3 years of follow up
|
Musculoskeletal adverse events will be graded using NCI CTC version 4.0
|
3 years of follow up
|
Activities of daily living, functional walking capacity and changes in balance
Tidsram: 3 years of follow up
|
3 years of follow up
|
|
Quality of life
Tidsram: 3 years of follow up
|
Using the Functional Assessment of Cancer Therapy General (FACT-G7) questionnaire
|
3 years of follow up
|
Nutritional status
Tidsram: 3 years of follow up
|
Using Mini Nutritional Assessment, weight, weight loss, albuminemia
|
3 years of follow up
|
Analgesics consumption
Tidsram: 3 years of follow up
|
issued from the exhaustive list of documented concomitant medications
|
3 years of follow up
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Claire Falandry, MD-PhD, Hospices Civils de Lyon
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2012-777
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada